• 1448 Citations
19992018

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My main research area is the development of targeted cancer therapeutics, e.g. pancreatic and ovarian cancer. Two drug classes are the focus of this work and act on complementing apoptosis pathways, the extrinsic and the intrinsic death pathways. The first drug class (biologic) represents an improved version of the TNF super family member TRAIL, a native tumor surveillance cytokine, genetically engineered into the stabilized drug platform, TR3. Tumor targeting of soluble TR3 substantially increases its bioactivity and is achieved via attachment to cancer-specific surface markers such as mesothelin and CA125. The other drug class (small molecule) has high affinity to the cancer-specific sigma-2 receptor. The corresponding ligands are harnessed as vehicles to deliver drug cargos (peptidomimetics) selectively into the cancer cells to augment the baseline killing capacity of the parental molecules. The ultimate goal is to evaluate the most promising drug candidates in human clinical trials alone, in combination with each other and standard chemotherapy.

Fingerprint Dive into the research topics where Dirk Spitzer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1448 Citations
  • 34 Article
  • 2 Comment/debate
  • 1 Letter
  • 1 Review article
  • 7 Scopus citations
    Open Access
  • 8 Scopus citations
    Open Access
  • 12 Scopus citations

    The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

    Hashim, Y. M., Vangveravong, S., Sankpal, N. V., Binder, P. S., Liu, J., Goedegebuure, S. P., Mach, R. H., Spitzer, D. & Hawkins, W. G., Jan 17 2017, In : Journal of Experimental and Clinical Cancer Research. 36, 1, 14.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Scopus citations

    Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic

    Ohman, K. A., Hashim, Y. M., Vangveravong, S., Nywening, T. M., Cullinan, D. R., Goedegebuure, S. P., Liu, J., Van Tine, B. A., Tiriac, H., Tuveson, D. A., DeNardo, D. G., Spitzer, D., Mach, R. H. & Hawkins, W. G., Jun 7 2016, In : Oncotarget. 7, 23, p. 33529-33541 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 10 Scopus citations